Yeramian Patrick D's Form 4 filing
Amylyx Pharmaceuticals, Inc. (AMLX) · filed Mar 20, 2023
- Accession no.
- 0000899243-23-009178
- Filed
- Mar 20, 2023
- Trade date
- Mar 16, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.74M. It was filed 4 days after the trade.
This filing was later replaced by the amendment 0000899243-23-009600 (Mar 24, 2023). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Yeramian Patrick DCIK 0001358266 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 16, 2023 | Common Stock | SSaleDisposed | −52,211 | $31.85F2 | −$1,662,920.35 | 152,088 | Direct | |
| Mar 16, 2023 | Common Stock | SSaleDisposed | −2,416 | $32.43F3 | −$78,350.88 | 149,672 | Direct | |
| Mar 16, 2023 | Common Stock | AGrant or awardAcquired | +9,167 | $0.00 | $0 | 158,839 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 16, 2023 | Common Stock | AGrant or awardAcquired | +41,250 | $0.00 | $0 | 41,250 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.26 to $32.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.28 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.